Submit an Abstract for ACoP6

Important Deadlines

March 31, 2015 Abstract Submissions Open
June 15, 2015 Abstract Submissions Deadline
July 15, 2015 Notification of Acceptance 


Submit an Abstract


Call for Abstracts!

Abstract submission to ACoP6 is now open through June 15th! The planning committee would like to invite you to submit your work and be part of the exciting science at the conference.

We are also excited to announce two new opportunities this year to showcase your work. For the first time, we will be featuring a poster session during the full day pre-conference. For pre-conference poster session, we are calling for works that relate to the application of both pharmacometric and biostatistical approaches to projects, preferably those that illustrate the complementarity and cooperative synergy of these two disciplines. If you are planning to attend the pre-conference, we encourage you to consider presenting your poster during both the pre-conference and main conference poster session. In addition, the programming committee is planning a dedicated session for abstract Quality and Trainee awardees to orally present their works.


Abstract Considerations

All submitted abstracts will be peer reviewed. Abstracts will be reviewed on the basis of:

Relevance to the discipline of pharmacometrics: defined as “the science of interpreting and describing pharmacology in a quantitative fashion”, or “the science of developing and applying mathematical and statistical methods to characterize, understand and predict a drug’s pharmacokinetic, pharmacodynamic and biomarker-outcomes behavior” (Ette and Williams, 2007).

Scientific content: abstract are expected to be scientific in nature and contain enough information to allow for scientific review (Are the methods described in sufficient detail? Does the abstract contain enough concrete evidence or results to support its conclusions? Are the results, either experimental or from computer simulation, quantitatively stated, either in table or graphical format? Alternatively, for abstracts describing a process, method or software, is the algorithm well described, has it been evaluated and are results presented? If the results are preliminary, are they characterized as such? Is the abstract purely or excessively commercial or promotional in nature?)

Background: an appropriate level of background information should be provided to allow audience and reviewers to assess the abstract impact (Is enough background provided for the reader to understand the abstract goal? Is the literature reviewed at least to some extent and in an unbiased manner? Are citations provided?)

Innovation: except for ENCORE presentations*, abstracts are expected to contain novel and significant information by some scientific criterion (Are the results methodologically innovative or otherwise significant? Do they shed light on certain aspects of pharmacotherapy for a particular disease? Is the methodology novel? If the methodology is not novel, is the application (to a particular problem or disease area) original? For an ENCORE submission, is the content particularly relevant to the discipline of pharmacometrics and the expected meeting audience?)

Style: abstracts should be concisely and clearly written, including structure, language, and overall exposition (Is the abstract main goal sufficiently clear? Are the results well summarized? Are there imprecision of language or errors of syntax and/or grammar? Are measurement units reported?)

*The conference may accept a limited number of selected ENCORE presentations. Their content should be particularly relevant to the discipline of pharmacometrics and the expected meeting audience. For ENCORE presentations, submitters should disclose the previous presentation in the body of the abstract and on the poster using the following suggested format: “The results in this abstract have been previously presented in part at [conference name, venue and date] and published in the conference proceedings as abstract [number]”.

Abstracts that do not comply with the guidelines may be rejected so please take the time to conform your submission.


Abstract Publication

All accepted abstracts will be published in a supplemental copy of the Journal of Pharamcokinetics and Pharmacodynamics


Abstract Guidance

Authors must adhere to a standardized format to allow for publishing. The general format of abstracts follows that of most major scientific meetings, and is described below:

Title: Abstract Title

Authors: List of all Authors

Institutions: Affiliations for listed Authors

Objectives: A brief description of the objectives/hypothesis of the work described

Methods: A brief description of the methods used to reach the stated objectives, or to test the hypothesis.

Results: A description of the results obtained

Conclusions: Conclusions that can be reached for the stated objectives and hypotheses.

References: References used to execute the work.

Maximum Word Count: 350, including Authors, Title, Institutions, and References

Maximum Number of Figures and Tables: One figure OR table (including a title) embedded in the abstract file

File Format: Word Document (example abstract in word format available here)


Poster Board Specifications




Posters will be displayed on standard poster boards 4 feet tall by 8 feet wide with a usable space of approximately 45 inches tall by 90 inches wide.  For optimal viewing, we recommend confining the displays to the 42 inches tall by 60 inches wide area in the center of  the poster board. Posters can be mounted on the poster boards using pushpins that will be provided at the meeting


Submit an Abstract

powered by MemberClicks